Meridian Bioscience Inc

Meridian Bioscience — William Blair Healthcare Conference 2019

26 slides from Meridian Bioscience's conference presentation, Jun 6, 2019

  1. Slide 1: William Blair Healthcare Conference

    William Blair Healthcare Conference Jack Kenny, Chief Executive Officer June 6, 2019 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the m

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures Certain financial measures presented in this presentation, such as operating expenses, operating income, net earnings and diluted earnings per share, excluding as applicable the effects of restructuring costs, litigation costs, goodwill impairment charge, and certain one-

  4. Slide 4: What Is Meridian Bioscience?

    What Is Meridian Bioscience? 2018 sales: $63M ~185 employees 6 locations in 5 countries Development and production of proprietary antibodies, antigens, and molecular reagents Capacity and expertise to supply high volume, high demand customers International footprint including China LIFE SCIENCE 2018

  5. Slide 5: Meridian Bioscience Overview

    FY18 Sales by Platform FY18 Sales by Region Core platforms Molecular (DNA Amplification) Rapid Immunoassay Enzyme-linked Immunoassay Blood Chemistry (Anodic Stripping Voltammetry, LeadCare® brand) Core products Gastrointestinal (H. pylori, C. difficile, EHEC, Campy) Respiratory (Group A Strep, Mycop

  6. Slide 6: Strategic Imperatives

    Manage competitive pressures and product life cycles Leverage cost structure and operational efficiency Focus resources on core target markets Redeploy available capital to support investment in the business Increase investment in R&D, acquisitions Strategic Imperatives G G G G G Reposition the busi

  7. Slide 7: Life Science

    Life Science eT

  8. Slide 8: Life Science Strategic Summary

    Pivot sales focus to high value accounts R&D consolidation: Centers of excellence Move to more cost effective approach to sell into academia (distribution, online, inside sales) Resource Utilization Leverage strong IA position in IVD (and China) to grow MDx Leverage strong MDx position in academia t

  9. Slide 9: Life Science Sample to Bulk Order

    Life Science Sample to Bulk Order ORDER VOLUME: Sample Orders Lot Orders Bulk Orders 6-12 months LEAD TIME: 12-24 months Customers Seek Regulatory Approvals Long lead time from sample to full bulk order High and consistent quality critical Sticky business as customers tend to avoid re-validation Str

  10. Slide 10: Life Science Financial Performance

    Annual Revenues (millions) Life Science Financial Performance +12% +10% Operating Margin 2019 and Beyond Opportunities: Continued outsourcing by IVD manufacturers New products for both IVD and research applications Growth of MDx market, globally Challenges: Recent shift in China demand environment O

  11. Slide 11: Diagnostics

    Diagnostics ~~

  12. Slide 12: Vision and Key Focus Activities

    Vision The health system’s (IDNs) trusted partner, spanning the continuum of care from the physician office to the hospital laboratory, delivering expertise and innovation in gastrointestinal disease testing and supporting the well-being of our children to improve health outcomes and build a healthi

  13. Slide 13: Strategic Positioning

    Strategic Positioning I D N I D N Physician Office Labs Large Hospitals Medium Hospitals Small Hospitals Allows selling across IDNs (small to large) Allows best-in-class technology for each assay (i.e. C. diff) GI Depth Dual Technology IA + MDx Pediatric POC Workstation Consolidation Allows for deep

  14. Slide 14: Acquisition of GenePOC and revogene Platform

    by Molecular Diagnostics Platform Acquisition of GenePOC and revogeneTM Platform

  15. Slide 15: GenePOC Strategic Fit and Rationale

    Adds state-of-the-art revogene™ molecular diagnostics platform Ideal fit for deep gastrointestinal and select respiratory strategy GenePOC Strategic Fit and Rationale FDA-cleared / CE-marked menu in place Market-ready to transition Meridian molecular diagnostics customers Strong development and engi

  16. Slide 16: revogene Workflow Sample-to-Answer

    Discharge sample Hands on time ~1 minute Collect sample Sample vortexing Load sample into the PIE Place PIE into system and start Results within 70 minutes 1 2 3 revogeneTM Workflow Sample-to-Answer

  17. Slide 17: GenePOC Operational Footprint

    R&D Team and Track Record Quebec-based team FDA cleared instrument 4 FDA cleared assays Novel consumable and instrument designs Manufacturing Footprint Pilot PIE assembly line in place since 2013 Used for R&D, RUO, and IUO lots Used for commercial IVD lots Current capacity of 700K PIEs/year/shift Ge

  18. Slide 18: revogene Competitive Positioning

    Ease of use # of Multiplex Targets 1-5 11-15 6-10 16-20 21+ Competitor A Simplified sample prep Efficient workflow Multiple sample types Random access PCR technology Multiplexing ability Flexible acquisition options Small footprint Intuitive user interface Bidirectional interface Low maintenance Rel

  19. Slide 19: Platform Differentiators

    low high simple complex small large low high FOOTPRINT / SIZE COST / SERVICE DESIGN COST Primary competitors Primary competitors Primary competitors Primary competitors Powerful instrument that fits in many types of customer segments cost-effectively Elegant consumable design with competitive advant

  20. Slide 20: Conversion of Molecular Customers

    Sustainably grow the base with menu expansion and increased competitive placements Stabilize and protect base with Alethia conversions Current trend of Meridian molecular revenues GenePOC acquisition Conversion of Molecular Customers All other MDx assays (including CMV and Malaria) C. difficile Grou

  21. Slide 21: Future Menu Positioning

    Future Menu Positioning Group B Strep Group A Strep C. difficile Carbapenemase (colony) Current revogeneTM Menu revogeneTM Menu and Potential Limited menu based on most common tests With the number of antibiotic- resistant bugs and therapies increasing, resistance testing is key Menu on both MDx and

  22. Slide 22: Current and Expanded Market Opportunities (U.S.)

    I D N I D N $21B 5,900 $32B 8,900 $3B 120,000 (11,700 CLIA) Physician Office Labs Independent Labs LAB Large Hospitals Medium Hospitals Small Hospitals Lab Revenues: Sites: Immunoassay DiaSorin Automated HpSA® ELISA HpSA® Curian™ C. diff | EHEC | Campy | HpSA® | Flu AB Rapids Foodborne | C. diff | H

  23. Slide 23: Financial Trends and Priorities and Direction

    Revenue (millions) Financial Trends Operating Income (millions) Life Science profitability and growth foundation Defend and maintain Diagnostics against increasing competitive pressures Accelerating growth with turnover of core Diagnostic products and platforms (2020-2021) Leverage restructuring act

  24. Slide 24: Strategic Imperatives

    Manage competitive pressures and product life cycles Leverage cost structure and operational efficiency Focus resources on core target markets Redeploy available capital to support investment in the business Increase investment in R&D, acquisitions G G G G G Reposition the business for sustainable,

  25. Slide 25: Appendix

    APPENDIX =~

  26. Slide 26: GAAP to Non-GAAP Reconciliations

    Meridian Bioscience, Inc. GAAP to Non-GAAP Reconciliations (In Thousands)

Meridian Bioscience — William Blair Healthcare Conference 2019 on 6ix